Literature DB >> 19458650

Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse.

T K Park1, Z Wu, S Kjellstrom, Y Zeng, R A Bush, P A Sieving, P Colosi.   

Abstract

X-linked juvenile retinoschisis (XLRS) is a neurodevelopmental abnormality caused by retinoschisin gene mutations. XLRS is characterized by splitting through the retinal layers and impaired synaptic transmission of visual signals resulting in impaired acuity and a propensity to retinal detachment. Several groups have treated murine retinoschisis models successfully using adeno-associated virus (AAV) vectors. Owing to the fragile nature of XLRS retina, translating this therapy to the clinic may require an alternative to invasive subretinal vector administration. Here we show that all layers of the retinoschisin knockout (Rs1-KO) mouse retina can be transduced efficiently with AAV vectors administered by simple vitreous injection. Retinoschisin expression was restricted to the neuroretina using a new vector that uses a 3.5-kb human retinoschisin promoter and an AAV type 8 capsid. Intravitreal administration to Rs1-KO mice resulted in robust retinoschisin expression with a retinal distribution similar to that observed in wild-type retina, including the expression by the photoreceptors lying deep in the retina. No off-target expression was observed. Rs1-KO mice treated with this vector showed a decrease in the schisis cavities and had improved retinal signaling evaluated by recording the electroretinogram 11-15 weeks after the application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458650      PMCID: PMC2774250          DOI: 10.1038/gt.2009.61

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  36 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

2.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Authors:  Artur V Cideciyan; Tomas S Aleman; Sanford L Boye; Sharon B Schwartz; Shalesh Kaushal; Alejandro J Roman; Ji-Jing Pang; Alexander Sumaroka; Elizabeth A M Windsor; James M Wilson; Terence R Flotte; Gerald A Fishman; Elise Heon; Edwin M Stone; Barry J Byrne; Samuel G Jacobson; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

3.  Psychophysical and electroretinographic findings in X-linked juvenile retinoschisis.

Authors:  N S Peachey; G A Fishman; D J Derlacki; M G Brigell
Journal:  Arch Ophthalmol       Date:  1987-04

4.  Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.

Authors:  Dirk Grimm; Shangzhen Zhou; Hiroyuki Nakai; Clare E Thomas; Theresa A Storm; Sally Fuess; Takashi Matsushita; James Allen; Richard Surosky; Michael Lochrie; Leonard Meuse; Alan McClelland; Peter Colosi; Mark A Kay
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

5.  A retinal neuronal developmental wave of retinoschisin expression begins in ganglion cells during layer formation.

Authors:  Yuichiro Takada; Robert N Fariss; Atsuhiro Tanikawa; Yong Zeng; Deborah Carper; Ronald Bush; Paul A Sieving
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

6.  RS-1 Gene Delivery to an Adult Rs1h Knockout Mouse Model Restores ERG b-Wave with Reversal of the Electronegative Waveform of X-Linked Retinoschisis.

Authors:  Yong Zeng; Yuichiro Takada; Sten Kjellstrom; Kelaginamane Hiriyanna; Atsuhiro Tanikawa; Eric Wawrousek; Nizar Smaoui; Rafael Caruso; Ronald A Bush; Paul A Sieving
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

Review 7.  X-linked retinoschisis: a clinical and molecular genetic review.

Authors:  Avinash Tantri; Tamara R Vrabec; Andrew Cu-Unjieng; Arcilee Frost; William H Annesley; Larry A Donoso
Journal:  Surv Ophthalmol       Date:  2004 Mar-Apr       Impact factor: 6.048

8.  Structure of adeno-associated virus serotype 5.

Authors:  Robert W Walters; Mavis Agbandje-McKenna; Valorie D Bowman; Thomas O Moninger; Norman H Olson; Michael Seiler; John A Chiorini; Timothy S Baker; Joseph Zabner
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 9.  Interphotoreceptor retinoid-binding protein--an old gene for new eyes.

Authors:  Federico Gonzalez-Fernandez
Journal:  Vision Res       Date:  2003-12       Impact factor: 1.886

10.  Mutations of the XLRS1 gene cause abnormalities of photoreceptor as well as inner retinal responses of the ERG.

Authors:  K Bradshaw; N George; A Moore; D Trump
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 1.854

View more
  70 in total

Review 1.  Gene therapy for ocular diseases.

Authors:  Melissa M Liu; Jingsheng Tuo; Chi-Chao Chan
Journal:  Br J Ophthalmol       Date:  2010-08-23       Impact factor: 4.638

Review 2.  AAV-mediated gene therapy in mouse models of recessive retinal degeneration.

Authors:  J-J Pang; L Lei; X Dai; W Shi; X Liu; A Dinculescu; J H McDowell
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

3.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Authors:  Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

Review 4.  Gene therapy and genome surgery in the retina.

Authors:  James E DiCarlo; Vinit B Mahajan; Stephen H Tsang
Journal:  J Clin Invest       Date:  2018-06-01       Impact factor: 14.808

5.  Breaking and Sealing Barriers in Retinal Gene Therapy.

Authors:  Joan W Miller; Luk H Vandenberghe
Journal:  Mol Ther       Date:  2018-08-11       Impact factor: 11.454

6.  Retinoschisin (RS1) interacts with negatively charged lipid bilayers in the presence of Ca2+: an atomic force microscopy study.

Authors:  Svetlana Kotova; Camasamudram Vijayasarathy; Emilios K Dimitriadis; Laertis Ikonomou; Howard Jaffe; Paul A Sieving
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

Review 7.  A comprehensive review of retinal gene therapy.

Authors:  Shannon E Boye; Sanford L Boye; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

8.  R102W mutation in the RS1 gene responsible for retinoschisis and recurrent glaucoma.

Authors:  Xiu-Feng Huang; Chang-Sen Tu; Dong-Jun Xing; De-Kang Gan; Ge-Zhi Xu; Zi-Bing Jin
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

9.  Effect of genome size on AAV vector packaging.

Authors:  Zhijian Wu; Hongyan Yang; Peter Colosi
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

10.  A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells.

Authors:  Ryan R Klimczak; James T Koerber; Deniz Dalkara; John G Flannery; David V Schaffer
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.